Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma

Author： Terasaki Mizuhiko   Abe Toshi   Miyagi Naohisa   Ogo Etsuyo   Shigemori Minoru  

Publisher： Springer Publishing Company

ISSN： 0167-594X

Source： Journal of Neuro-Oncology, Vol.81, Iss.3, 2007-02, pp. : 265-269

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells

By Tanaka Kazuhiro   Sasayama Takashi   Mizukawa Katsu   Kawamura Atsufumi   Kondoh Takeshi   Hosoda Kohkichi   Fujiwara Toshiyoshi   Kohmura Eiji  

Journal of Neuro-Oncology, Vol. 84, Iss. 3, 2007-09 ,pp. : 233-244

Springer Publishing Company

Access to resources Recommend Favorite

Gene expression profiles of 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU)-resistant C6 rat glioma cells

By Nakagawa Takao   Kubota Toshihiko   Ido Kazunori   Sakuma Takahiro   Matsuda Ken  

Journal of Neuro-Oncology, Vol. 79, Iss. 3, 2006-09 ,pp. : 271-279

Springer Publishing Company

Access to resources Recommend Favorite

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

By Eisele Günter   Wick Antje   Eisele Anna-Carina   Clément Paul   Tonn Jörg   Tabatabai Ghazaleh   Ochsenbein Adrian   Schlegel Uwe   Neyns Bart   Krex Dietmar   Simon Matthias   Nikkhah Guido   Picard Martin   Stupp Roger   Wick Wolfgang   Weller Michael  

Journal of Neuro-Oncology, Vol. 117, Iss. 1, 2014-03 ,pp. : 141-145

Springer Publishing Company

Access to resources Recommend Favorite

Steroid management in newly diagnosed glioblastoma

By Deutsch Mariel  

Journal of Neuro-Oncology, Vol. 113, Iss. 1, 2013-05 ,pp. : 111-116

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

By Gerstner Elizabeth   Eichler April   Plotkin Scott   Drappatz Jan   Doyle Colin   Xu Lei   Duda Dan   Wen Patrick   Jain Rakesh   Batchelor Tracy  

Journal of Neuro-Oncology, Vol. 103, Iss. 2, 2011-06 ,pp. : 325-332

Springer Publishing Company

Access to resources Recommend Favorite